United TherapeuticsBSP:U2TH34 65 Days Inventory is 126.31 as of Mar. 2026, which is 50% below its 10-year median of 252.16. GuruFocus rates BSP:U2TH34 with a GF Score™ of 65/100 and a GF Value™ of R$97.21 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 919 Drug Manufacturers companies, United Therapeutics ranks better than 56.47% on this metric.
The historical rank and industry rank for United Therapeutics's Days Inventory or its related term are showing as below:
BSP:U2TH34'
s Days Inventory Range Over the Past 10 Years
Min: 149.76 Med: 252.16 Max: 455.12
Current: 149.76
During the past 13 years, United Therapeutics's highest Days Inventory was 455.12. The lowest was 149.76. And the median was 252.16.
BSP:U2TH34's Days Inventory is ranked better than 56.47% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs BSP:U2TH34: 149.76
United Therapeutics's Days Inventory
declined
from Mar. 2025 (164.10) to Mar. 2026 (126.31).
Inventory Turnover measures how fast the company turns over its inventory within a year.
United Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.72.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
United Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.24.
United Therapeutics (BSP:U2TH34) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
United Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
United Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
United Therapeutics Days Inventory Related Terms
United Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:U2TH34 vs VTRS, NBIX, ZTS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (BSP:U2TH34) has a Days Inventory of 126.31 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on United Therapeutics and its competitors. This is 50% below median its historical median of 252.16. Over the past decade, United Therapeutics' Days Inventory has ranged from 149.76 to 455.12. According to the industry distribution chart, United Therapeutics ranks #400 out of 919 companies in the Drug Manufacturers industry, placing it in the top 43.5%.
Is United Therapeutics' Days Inventory too high?
United Therapeutics' current Days Inventory of 126.31 is 50% below median its 10-year median of 252.16. Over the past 10 years, this metric has ranged from a low of 149.76 to a high of 455.12. The Drug Manufacturers industry median Days Inventory is 164.48. United Therapeutics' value of 126.31 is 23.2% below this industry median. Based on the distribution chart, United Therapeutics ranks #400 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Days Inventory compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #400 out of 919 companies for Days Inventory. This puts United Therapeutics in the upper half of its industry. The industry median Days Inventory is 164.48. United Therapeutics' value of 126.31 is 23.2% below this benchmark. Historically, United Therapeutics' own Days Inventory has ranged from 149.76 to 455.12 over the past decade. While the company's 10-year median is 252.16 vs. the industry median of 164.48, United Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Days Inventory of 126.31 is 23.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Days Inventory is 126.31, which is 50% below median its own 10-year median of 252.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (BSP:U2TH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$97.21, compared to a current price of R$137.50 — trading 41.4% above its estimated fair value. The current Days Inventory is 126.31, which is 50% below median its 10-year median of 252.16 and 23.2% below the Drug Manufacturers industry median of 164.48. United Therapeutics' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Days Inventory is 126.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of R$137.50 is trading 41.4% above its estimated GF Value™ of R$97.21.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for BSP:U2TH34:
Days Inventory: 126.31 (50% below median its 10-year median of 252.16)
GF Value™: R$97.21 vs. price of R$137.50 (41.4% above fair value)
Industry Position: 23.2% below the Drug Manufacturers median (#400 of 919)
No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score
Get the complete analysis for BSP:U2TH34
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:U2TH34 has been successfully added to your 
